Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy.
BACKGROUND
Juvenile myoclonic epilepsy (JME) is classified as primarily generalized epilepsy and as such is assumed to lack an anatomic substrate. Although neurochemical abnormalities are probable, few studies have investigated whether they exist in JME. Animal data and the high incidence of myoclonic seizures in serotonin-intoxicated patients suggest that the serotonin system may be disturbed in JME.


OBJECTIVE
To test the hypothesis that JME is associated with a disturbed serotonin system and that this disturbance could be reflected in altered serotonin 1A receptor binding.


METHODS
The serotonin 1A receptor binding potential (BP) was measured with positron emission tomography and serotonin 1A receptor antagonist carbonyl-carbon 11-WAY-100635. The BP was calculated using a reference tissue model in several limbic and neocortical regions and the raphe nuclei.


METHODS
Epilepsy clinics of the Karolinska University Hospital, Stockholm, Sweden.


METHODS
Eleven patients with JME and 11 controls were studied.


METHODS
Serotonin 1A receptor BP calculated in a set of volumes of interest.


RESULTS
The patients with JME showed a reduced BP in the dorsolateral prefrontal cortex, raphe nuclei, and hippocampus.


CONCLUSIONS
The observed reductions in serotonin 1A receptor BP suggest that the serotonin system is affected in JME. Although the data give no definitive information about underlying mechanisms, they provide a strong argument for the view that not all brain regions are homogeneously involved in this condition, further questioning the current classification of primarily generalized epilepsy.
Meschaks
Anna
A
Division of Neurology, NEUROTEC, Stockholm, Sweden.
Lindstrom
Per
P
Halldin
Christer
C
Farde
Lars
L
Savic
Ivanka
I
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D015536:Down-Regulation; D005260:Female; D006801:Humans; D008297:Male; D020190:Myoclonic Epilepsy, Juvenile / Q000000981:diagnostic imaging / Q000378:metabolism*; D010879:Piperazines / Q000378:metabolism; D049268:Positron-Emission Tomography / Q000379:methods; D011485:Protein Binding / Q000502:physiology; D011725:Pyridines / Q000378:metabolism; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism*
D010879:Piperazines; D011725:Pyridines; D044282:Receptor, Serotonin, 5-HT1A; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide